



EuroScore II and STS score: are they similar?

Julien Magne, PhD CHU Limoges, France



www.eurovalvecongress.com



EUroValve October 24-25, 2014

Faculty disclosure Julien Magne

I have **no financial relationships** to disclose.



www.eurovalvecongress.com

© 2000 Ted Goff www.tedgoff.com



"You're not allowed to use the sprinkler system to keep your audience awake."





Discrimination vs. Calibration

The best predictive score should have both good discrimination and calibration

Discrimination: ability to differentiate between low- and high-risk patients



Calibration: comparison between predicted and observed end-point (e.g. mortality)



Durand et al. AJC, 2013





European System for Cardiac Operative Risk Evaluation (EuroSCORE) II

n=22 381 consecutive patients undergoing cardiac surgery in 154 hospitals, 43 countries during 12-week (May-July 2010)

	Patient related factors		Cardiac re	elated factors				
Age ¹ (years)	75	0.46	NYHA	II •	.1070545			
Gender	male -	0	CCS class 4 angina ⁸	no 🔹	0			
Renal impairment ² See calculator below for creatinine clearance	normal (CC >85ml/min) 🔹	0	LV function	moderate (LVEF 31%-50%) -	.3150652			
Extracardiac arteriopathy ³	no 🔻	0	Recent MI ⁹	yes -	.1528943			
Poor mobility ⁴	no 🔻	0	Pulmonary hypertension ¹⁰	no -	0			
Previous cardiac surgery	no 🔻	0	Operation	related factors				
Chronic lung disease ⁵	no 🔹	0	Urgency ¹¹	elective -	0			
Active endocarditis ⁶	no 🔻	0	Weight of the intervention ¹²	2 procedures -	.5521478			
Critical preoperative state ⁷	no 🔹	0	Surgery on thoracic aorta	no •	0			
Diabetes on insulin	no 👻	0						
EuroSCORE II + EuroSCORE	2.88 %							
Note: This is the 2011 EuroSCORE II	Calculate Clear							

Validation subset: 5 553 patients

http://www.euroscore.org/calc.html

Nashef et al. EJCTS, 2012





Euroscore II





Very good discrimination and calibration Observed mortality: 4.18% Expected mortality: 3.95%

Nashef et al. EJCTS, 2012





Good discrimination, Low calibration in high risk patients



Barili et al. EHJ, 2012



Predicted probability

EuroValve



Online STS Risk Calculator Dataset 2.72		Definiti	ions			the main di	fference between	
· · ··································			Supp	ort			Europe	e and USA
Help	More about Risk Calc	ulator	New	Print	Calculations		****	
		Today's Date	10/21/2014		Procedure Name	AVRepl+CABG		2 6 ft. 88 in,
Procedure					Risk of Mortality	1.485%	0.001 km =	42.8 yd
Trocedure					Morbidity or Mortality	12.008%	1 m =	88.263 nm
	Coronary Artery Bypass				Long Length of Stay	4.973%	100 cm =	2 3.1
	Valve Surgery	Yes ○ No ○ Missing			Short Length of Stay	46.469%	$100000 \mu m =$	
	Aortic	Yes ○ No ○ Missing			Permanent Stroke	1.198%	1000000000 nm	
	Aortic Procedure	Replacement			Prolonged Ventilation	6.437%		77
		Repair/Reconstruction			DSW Infection	0.208%		
		Root Reconstruction with valved conduit			Renal Failure	2.536%		
		 Replacement and insertion aortic non-valved conduit Resuspension Aortic Valve without replacement of asc 	ending		Reoperation	7.592%		
		Aorta						
		 Resuspension Aortic Valve with replacement of ascen Apico-aortic conduit (Aortic valve bypass) 	ding Aorta				an the	HELPI
		 Autograft with pulmonary valve- Ross procedure 						h
		O Homograft					75	
		 Valve sparing root reimplantation (David) Valve sparing root remodeling (Yacoub) 						
		○ Missing						
0 Resectio	n of Sub-Aortic Stenosis	○ Yes ○ No					N.	
0	Mitral	⊙Yes ⊙No ⊛ Missing						
0	Tricuspid							
<u> </u>	medapid	 Annuloplasty Only 						
		© Replacement					- 11	and the second se
		○ Reconstruction with Annuloplasty						~
		Reconstruction without Annuloplasty Nahoctomy						22
		valvecionity						100

Shahian et al., "Part 1-3" Ann Thorac Surg, 2009





STS Score

STS isolated valve surgery (n= 109 759)

STS valve + CABG (n=101 661)



Good discrimination but limited calibration in high risk patients

Shahian et al. "Part 2", ATS, 2009

Shahian et al. "Part 3", ATS, 2009





EuroSCORE II Vs. STS Score

Variable	EuroSCORE	EuroSCORE II	STS Scor
Age	Х	Х	Х
Gender	X	Х	Х
Height			Х
Weight			Х
Body mass index			Х
Diabetes mellitus		Х	X
Chronic lung/pulmonary disease	Х	Х	Х
Mild/moderate/severe			Х
Extracardiac arteriopathy	Х	Х	
Peripheral vascular disease			X
Neurologic dysfunction	X		
Cerebrovascular accident			Х
Poor mobility		X	
Previous cardiac surgery	Х	Х	Х
Number of previous operations			Х
Previous coronary bypass			Х
Previous valve surgery			Х
Renal failure/impairment	Х	X	Х
Dialysis-dependent renal		Х	Х
Serum creatinine/clearance		X	X
Hypertension			X
Active endocarditis	X	X	X
Immunosuppressive therapy	Α	71	X
Arrhythmia			X
Recent myocardial	X	Х	X
infarction		~*	

Variable	EuroSCORE	EuroSCORE II	STS Score
Timing Cardiogenic shock			X X
Inotropic agents			Х
Intra-aortic balloon pump			Х
New York Heart		Х	X
Association			
classification			
Unstable angina/Canadian	Х	Х	Х
Cardiovascular Society			
class IV angina			
Critical preoperative state	X	X	
Left ventricular ejection	Х	X	Х
function			
Number of diseased			X
coronary vessels			
Left main coronary artery			х
disease			
Pulmonary hypertension	X		
(>60 mm Hg)			
Moderate		X	
(31–55 mm Hg),			
severe (>55 mm Hg)			
Procedure status/urgency	Х	Х	Х
Weight of intervention	Х	X	X
Single noncoronary	Х	Х	
bypass/2 or 3			
procedures			

Durand et al., AJC, 2013



Euroscore II AUC= 0.70

0.8

1.0

STS AUC= 0.59

0.6

Log Euroscore AUC= 0.61

1.0

0.8

0.6

0.4

0.2

0 4

0.2

0.4

Sensitivity



EuroSCORE II Vs. STS Score

- n=350 TAVI patients
- Euroscore II provided better discrimination and calibration
- STS underestimated mortality

Stähli et al., Cardiology, 2013







EuroSCORE II Vs. STS Score

Risk Score	AUC (I-Index)	95% CI	p Value	
Log EuroSCORE				
Overall	0.63	0.51 - 0.76	0.06	
TF	0.66	0.53 - 0.89	0.06	
ТА	0.55	0.32 - 0.78	0.68	
EuroSCORE II				
Overall	0.66	0.52 - 0.79	0.02	
TF	0.71	0.55 - 0.88	0.01	
ТА	0.52	0.29 - 0.74	0.90	
STS score				
Overall	0.58	0.43-0.73	0.24	
TF	0.66	0.50 - 0.82	0.06	
TA	0.55	0.17-0.73	0.67	

n=250 TAVI patients (TA and TF) Good calibration but limited discrimination Euroscore II better than STS ?











EuroSCORE II Vs. STS Score

n=360 TAVI patients: Transapical approach only



In-hospital mortality



Haensig et al., EJCTS, 2013





EuroSCORE II Vs. STS Score: Meta-Analysis



Biancari et al., J CTV Anesthesia, in press



EuroSCORE II Vs. STS Score: Meta-Analysis



NS difference between Obs. and Exp. Mortality (p=0.88) Obs / Exp ratio

S difference between Obs. and Exp. Mortality (p=0.008)

		EuroScore II	STS score
7	SAVR	0.94	0.84
N	TAVI	1.23	1.13

Biancari et al., J CTV Anesthesia, in press





Take Home Messages!

- ✓ Risk scores should be calculated in order to assess the risk of intervention in patients with VHD, but limitations should be acknowledged.
- ✓ Both EuroSCORE II and STS score provide good discrimination but limited calibration in high risk patients
- ✓ Risk scores progressively improve but need to be frequently updated
- Although not specifically derived from VHD cohort, EuroSCORE II seems a bit better than STS score to assess the operative risk in overall aortic valve intervention
- ✓ Both scores seem underpredicted the risk of TAVI

Join us in Vienna! 3 - 6 December 2014

Euro Echo2014 ¹⁸ Annual Meting of the European Association of Cardiolosacular Imaging a registered branch Monting Group of Extractandog april Monting Group of Extrac

Still time to REGISTER



EuroEcho-Imaging at your fingertips!

Download the **Mobile App** and stay up to date with the scientific programme!

Search for **"EuroEcho2014**" in App Store/Google Pla



vailable on iOS and Android



VIENNA AUSTRIA 3-6 DECEMBER



www.escardio.org/EACVI



EuroSCORE II Vs. STS Score: Meta-Analysis







The Place of Scores in Current Guidelines

"In the absence of evidence from RCT, the decision to intervene in a patient with VHD relies on an individual **risk-benefit analysis** suggesting that improvement of prognosis, as compared with natural history, outweighs the **risk of intervention** and its **potential late consequences**, particularly prosthesis-related complications"

> ESC Guidelines 2012 ACC/AHA Guidelines 2014

	AS	AR	MS	Primary MR	TR
Surgery vs. Percutaneous	"Heart Team" + risk score		"Heart Team" + risk score	"Heart Team" + risk score	
Asymptomatic	Preserved LVEF: Low risk	Preserved LVEF: Low risk		Low risk	
Symptomatic				Low comorbidities	